CHF and arrhythmias:
Indications for: COREG
Mild to severe heart failure (HF), to increase survival and reduce hospitalization risk. To reduce cardiovascular mortality post-MI with left ventricular ejection fraction ≤40%.
Adult Dosage:
Take with food. Monitor dose increases closely. ≥18yrs: CHF: initially 3.125mg twice daily for 2 weeks, may double dose every 2 weeks if tolerated; mild to moderate HF (>85kg): usual max 50mg twice daily. Reduce dose if pulse <55. Post-MI: initially 6.25mg twice daily; increase to 12.5mg twice daily after 3–10 days if tolerated; then to target dose 25mg twice daily. Low BP or heart rate, or fluid retention: may start at 3.125mg twice daily.
Children Dosage:
<18yrs: not recommended.
COREG Contraindications:
Cardiogenic shock or decompensated HF requiring intravenous inotropic therapy. Asthma, related bronchospastic conditions. 2nd or 3rd-degree AV block, sick sinus syndrome, or severe bradycardia, unless paced. Severe hepatic impairment.
COREG Warnings/Precautions:
Peripheral vascular disease. Nonallergic bronchospasm. Diabetes (monitor blood glucose). Hyperthyroidism. Monitor renal function in ischemic heart disease, diffuse vascular disease, underlying renal insufficiency, and/or if systolic BP <100 mmHg. Initiation of therapy may temporarily worsen signs and symptoms; benefits may be delayed for several weeks; may need increased diuretic dose at first. Avoid abrupt cessation. Prinzmetal's angina. Pheochromocytoma. Elderly. Pregnancy. Nursing mothers.
See Also:
COREG Classification:
Noncardioselective beta-blocker/alpha-1 blocker.
COREG Interactions:
May be potentiated by CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine, propafenone), alcohol (separate by 2 hours). Bradycardia, hypotension with catecholamine depletors (eg, reserpine, MAOIs). Carvedilol levels reduced by rifampin. Increased absorption with cimetidine. Caution with drugs that affect cardiac conduction (esp. diltiazem, verapamil). May potentiate antidiabetic agents. Monitor digoxin, cyclosporine when changing carvedilol dose. Anesthesia.
Adverse Reactions:
Dizziness, edema, hypotension, syncope, bradycardia, AV block, GI upset, hyperglycemia, weight gain, abnormal vision.
How Supplied:
CR caps—30, 90; Tabs—100
Hypertension:
Indications for: COREG
Hypertension.
Adult Dosage:
Take with food. ≥18yrs: initially 6.25mg twice daily; may increase as tolerated at 1–2 week intervals to 12.5mg twice daily. Max 25mg twice daily.
Children Dosage:
<18yrs: not recommended.
COREG Contraindications:
Cardiogenic shock or decompensated HF requiring intravenous inotropic therapy. Asthma, related bronchospastic conditions. 2nd or 3rd-degree AV block, sick sinus syndrome, or severe bradycardia, unless paced. Severe hepatic impairment.
COREG Warnings/Precautions:
Peripheral vascular disease. Nonallergic bronchospasm. Diabetes (monitor blood glucose). Hyperthyroidism. Monitor renal function in ischemic heart disease, diffuse vascular disease, underlying renal insufficiency, and/or if systolic BP <100mmHg. Avoid abrupt cessation. Prinzmetal's angina. Pheochromocytoma. Elderly. Neonates. Pregnancy (monitor). Nursing mothers.
See Also:
COREG Classification:
Noncardioselective beta-blocker/alpha-1 blocker.
COREG Interactions:
May be potentiated by CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine, propafenone), alcohol (separate by 2 hours). Bradycardia, hypotension with catecholamine depletors (eg, reserpine, MAOIs). Carvedilol levels reduced by rifampin. Increased absorption with cimetidine. Caution with drugs that affect cardiac conduction (esp. diltiazem, verapamil). May potentiate antidiabetic agents. Monitor digoxin, cyclosporine when changing carvedilol dose. Anesthesia.
Adverse Reactions:
Bradycardia, orthostatic hypotension, dizziness, nasopharyngitis, GI upset, edema.
How Supplied:
CR caps—30, 90; Tabs—100
